

# Selenoprotein P is the essential selenium transporter for bones†

Nicole Pietschmann,<sup>ab</sup> Eddy Rijntjes,<sup>a</sup> Antonia Hoeg,<sup>ab</sup> Mette Støedter,<sup>a</sup> Ulrich Schweizer,<sup>c</sup> Petra Seemann<sup>d</sup> and Lutz Schomburg<sup>\*a</sup>

Cite this: *Metallomics*, 2014, 6, 1043

Received 7th January 2014,  
Accepted 24th February 2014

DOI: 10.1039/c4mt00003j

[www.rsc.org/metallomics](http://www.rsc.org/metallomics)

Selenium (Se) plays an important role in bone physiology as best reflected by Kashin–Beck disease, an endemic Se-dependent osteoarthritis. Bone development is delayed in children with mutations in SECIS binding protein 2 (SBP2), a central factor for selenoprotein biosynthesis. Circulating selenoprotein P (SePP) is positively associated with bone turnover in humans, yet its function for bone homeostasis is not known. We have analysed murine models of altered Se metabolism. Most of the known selenoprotein genes and factors needed for selenoprotein biosynthesis are expressed in bones. Bone Se is not associated with the mineral but exclusively with the organic matrix. Genetic ablation of Sepp-expression causes a drastic decline in serum (25-fold) but only a mild reduction in bone (2.5-fold) Se concentrations. Cell-specific expression of a SePP transgene in hepatocytes efficiently restores bone Se levels in Sepp-knockout mice. Of the two known SePP receptors, Lrp8 was detected in bones while Lrp2 was absent. Interestingly, Lrp8 mRNA concentrations were strongly increased in bones of Sepp-knockout mice likely in order to counteract the developing Se deficiency. Our data highlight SePP as the essential Se transporter to bones, and suggest a novel feedback mechanism for preferential uptake of Se in Se-deprived bones, thereby contributing to our understanding of hepatic osteodystrophy and the consistent bone phenotype observed in subjects with inherited selenoprotein biosynthesis mutations.

## Introduction

The essential trace element selenium (Se) plays an important role in human health.<sup>1</sup> A low Se status is related to a higher risk of *e.g.* cancer reported in the majority of experimental animal and human studies.<sup>2</sup> Mortality has been shown to inversely correlate with blood Se concentrations in critical illness<sup>3</sup> and renal cancer<sup>4</sup> highlighting the outstanding importance of Se as an essential micronutrient. Se status, however, varies considerably between human populations worldwide as it depends on dietary Se, which in turn is decisively controlled by soils used for agricultural food production.<sup>5</sup> The global dietary intakes range from 7 to 220 µg Se per day,<sup>6</sup> and large parts of Europe, Asia and Africa must be considered as areas with insufficient Se

supply from natural resources. In addition, the dietary preferences, the personal genotype and the general health state are important modifiers of Se metabolism and status.

Upon reduced intake, Se concentrations decline in serum, liver, kidney and other tissues. Notably, the central nervous system and the endocrine organs are largely resistant to a limited Se supply. These organs retain their privileged Se status even in experimental models of severe Se deficiency.<sup>7</sup> Such a hierarchical dependence on the Se status is observed on both the tissue level and with respect to different selenoproteins,<sup>8</sup> ensuring that the most essential Se-dependent processes are maintained in privileged tissues even in times of severe Se deficiency.<sup>9</sup>

Se exerts its effects mainly in the form of selenocysteine (Sec), the 21st proteinogenic amino acid. Sec-dependent selenoproteins are encoded by a set of 25 human and 24 murine genes, respectively.<sup>10</sup> Biosynthesis of selenoproteins requires the re-coding of a UGA stop-codon within the open reading frame of selenoprotein transcripts. The co-translational incorporation of Sec into growing selenoproteins depends on the interaction of a set of Sec-specific *trans*- and *cis*-acting factors including Sec-loaded tRNA<sup>[Ser]Sec</sup>, a Sec insertion sequence (SECIS) element in selenoprotein transcripts, which is recognized by the rate-limiting RNA-binding factor SECIS binding protein-2 (SBP2).<sup>11</sup> In addition, two Se-binding proteins involved in intracellular Se metabolism have been described, *i.e.*, the 56 kDa

<sup>a</sup> Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, D-13353 Berlin, Germany. E-mail: [lutz.schomburg@charite.de](mailto:lutz.schomburg@charite.de); Fax: +49 30 450524922; Tel: +49 30 450524289

<sup>b</sup> Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité-Universitätsmedizin Berlin, Germany

<sup>c</sup> Institut für Biochemie und Molekularbiologie, Rheinische Friedrich-Wilhelms-Universität Bonn, D-53115 Bonn, Germany

<sup>d</sup> Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, D-13353 Berlin, Germany

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c4mt00003j



Se-binding protein-1 (SELENBP-1) and 14 kDa fatty acid-binding protein-1 (FABP-1).<sup>12</sup> Within the cell, Se is liberated and reduced to selenide before becoming phosphorylated by the Se-dependent selenophosphate synthetase-2 (SEPHS2). In parallel, seryl-loaded tRNA<sup>[Ser]<sup>Sec</sup></sup> is phosphorylated by phosphoseryl-tRNA kinase (PSTK). Combination of these two energy rich substrates to Sec-loaded tRNA<sup>[Ser]<sup>Sec</sup></sup> is catalyzed by P-Ser-tRNA:Sec-tRNA synthase (SEPSECS). The Sec-specific elongation factor EFsec and nucleolin (NCL) finally contribute to the co-translational insertion of Sec along with additional translation factors.<sup>11</sup>

Among the mammalian selenoproteins, selenoprotein P (SePP) is unique as it carries multiple Sec residues per protein and constitutes the majority of Se in blood.<sup>13</sup> SePP decisively contributes to the hierarchical Se supply of brain and testis.<sup>14</sup> Two receptors of the lipoprotein receptor related protein (LRP) family have been identified as SePP receptors, *i.e.*, LRP2 (Megalin) and LRP8 (ApoER2).<sup>15,16</sup> Serum Se and SePP concentrations correlate over a wide range of nutritional Se intake. Once Se supply is sufficient, SePP biosynthesis is saturated thereby becoming independent of further Se intake.<sup>17</sup> The threshold at which maximal expression of SePP is observed is used to define the optimal nutritional intake range for Se.<sup>18</sup>

The physiological role of SePP was analysed in mouse models with modified Sepp expression.<sup>19</sup> Homozygous Sepp knockout (Sepp<sup>-/-</sup>) mice display a Se-dependent phenotype with a tissue-specific Se deficit, a reduced growth rate, ataxia and male-specific infertility.<sup>20,21</sup> The neurological phenotypes are replicated in Lrp8 knockout mice, highlighting the mutual dependence of brain Se homeostasis on Sepp and Lrp8.<sup>22,23</sup>

A central importance of Se for bones is becoming increasingly recognized.<sup>24</sup> Upon low dietary Se intake, rodents develop a bone phenotype characterized by poorly developed cortical and trabecular mineralization.<sup>25</sup> In humans, Se deficiency is associated with Kashin-Beck disease (KBD), an endemic degenerative osteoarthritis, which is preventable by Se supplementation.<sup>26</sup> Subjects with inherited defects in SBP2 display reduced selenoprotein expression, a disturbed thyroid hormone pattern in blood and consistently a drastically delayed bone development and relatively short stature.<sup>27–29</sup> Recently, we have reported that serum SePP concentrations are associated with markers of bone turnover and bone mineral density.<sup>30</sup> With this study, we evaluated the importance of SePP for bone Se metabolism. Bones turned out to dynamically express the SePP receptor Lrp8 and to depend on liver-derived SePP for efficient Se uptake thereby representing a preferentially supplied target organ residing high in the hierarchy of tissue-specific Se supply, similar to brain and the classical endocrine organs. In hindsight, this metabolic privilege makes perfect sense, as bones are equally important as brain and the endocrine organs for growth and survival.

## Materials and methods

### Experimental animals

Animal maintenance was in accordance with the Guide for the Care and Use of Laboratory animals: 8th ed. and had been

approved by the local authorities (LaGeSo Berlin, Germany). Sepp wildtype (Sepp<sup>+/+</sup>), heterozygous (Sepp<sup>+/-</sup>) and homozygous knockout (Sepp<sup>-/-</sup>) mice were raised and backcrossed on a C57/BL6 background as described.<sup>20</sup> In addition, homozygous Sepp<sup>-/-</sup> mice expressing a human SePP transgene in liver only (Sepp<sup>-/-tg</sup>) were genotyped and reared as described.<sup>14</sup> Mice were bred and raised on a rodent diet containing a defined amount of Se equal to the Recommended Daily Allowance (RDA) for mice (Altromin C1045, Lage, Germany, supplemented with Na-selenite to 0.15 ppm as described<sup>31</sup>). Mice were sacrificed at postnatal day 35–40 (P35–40) in order to isolate serum and tissues for further analyses.

### RNA extraction

Bones were prepared free of surrounding tissues and powdered with a steel ball in a teflon capsule using a Mikro-Dismembrator (B. Braun, Melsungen, Germany) under liquid nitrogen. Total RNA extractions from tibia and femur powder were performed using TRIzol<sup>®</sup> Reagent (PEQLAB, Erlangen, Germany) according to the manufacturer's instructions. RNA was further purified by one round of chromatography using RNeasy Mini columns (QIAGEN, Hilden, Germany).

### Quantitative reverse transcription-PCR (qRT-PCR)

RNA samples were reverse-transcribed using the iScript<sup>™</sup> Select cDNA Synthesis Kit (BIO-RAD, Munich, Germany). qRT-PCR analyses were performed using the iCycler-System (BIO-RAD) and Absolute QPCR SYBR Green Fluorescein Mix (Thermo Scientific, Schwerte, Germany). A melting curve analysis was performed at the end of each qRT-PCR analysis in order to verify specificity of the primer pairs and amplicons. All results were normalized to 18S rRNA concentrations and compared to Sepp<sup>+/+</sup> wildtype mice as the reference condition. Appropriate primer pairs for all 24 murine selenoprotein genes and important factors for selenoprotein biosynthesis and Se metabolism were designed with the primer3plus database (Table S1, ESI<sup>†</sup>).<sup>32</sup> Gene expression was considered as absent when specific amplicons were not obtained after 40 cycles of qRT-PCR (Table 1).

### Western blot analyses

Murine femurs were powdered under liquid nitrogen using a steel ball in 2 ml polypropylene reaction tubes for 1 min at 20/s in a TissueLyser (Qiagen). Homogenization buffer (0.25 M sucrose; 20 mM HEPES; 1 mM EDTA, pH 7.4) was added, vortexed and the homogenate was sonified. Cytosolic fractions were obtained after centrifugation for 10 min at 20 000 × g, 4 °C. Pellets were resuspended and solubilized in RIPA buffer (50 mM Tris/HCl pH 8.0; 150 mM NaCl; 1% NP-40; 0.5% Na-deoxycholate; 0.1% SDS) for obtaining membrane fractions. After incubation on ice (30 min) and a centrifugation step (20 min at 20 000 × g; 4 °C), fractions were collected and stored at -40 °C until analysis.

Protein concentrations of cytosolic fractions were quantified by a BIO-RAD Protein Assay using IgG as standard (BIO-RAD). A Pierce<sup>®</sup> BCA Protein Assay (Thermo Scientific) was used for the membrane fractions using BSA as standard. Samples containing



**Table 1** Effects of SePP deficiency on selenoprotein transcript levels in bones<sup>a</sup>

Gene	Sepp <sup>+/-</sup>	Sepp <sup>-/-</sup>	Gene	Sepp <sup>+/-</sup>	Sepp <sup>-/-</sup>
Gpx1	1.6	1.0	Seli	1.5	5.4
Gpx2	0.8	0.7*	Selk	1.7	0.3**
Gpx3	1.1	0.7*	Selm	1.4	0.7*
Gpx4	2.4	0.3*	Selo	1.8*	1.1
Dio1	— <sup>b</sup>	— <sup>b</sup>	Selt	1.1	1.1
Dio2	1.1	1.2	Selv	— <sup>b</sup>	— <sup>b</sup>
Dio3	3.7	0.3	Sels	1.3	3.1
Txrd1	1.4	2.2	Sbp2	1.5	1.3
Txrd2	1.4	1.7	Selenbp1	1.3	1.4
Txrd3	1.7*	1.6	Secp43	1.7	1.4
Sephs2	1.5	1.5	Eif4a3	1.5	1.9
Sepp	0.4*	0.0***	Fabp1	0.8	2.1
Selr	1.2	0.7	Ncl	1.4	1.9
Seppn	1.4	0.9	Lrp1	1.5	5.4***
Sep15	2.0	0.8	Lrp2	— <sup>b</sup>	— <sup>b</sup>
Selw	1.7	2.9	Lrp8	1.5	6.0*
Selh	2.0	1.2			

<sup>a</sup> Differences in relative expression levels are shown ( $n = 6$ , Dunnett's  $t$  test). Expression is normalized to 18S rRNA and compared to Sepp<sup>+/+</sup> (ratio = 1.0). <sup>b</sup> Below detection limit (Ct > 40).

20 or 50  $\mu\text{g}$  protein were size fractionated by SDS-PAGE and blotted by semi-dry transfer onto nitrocellulose membranes (Optitran, Schleicher & Schuell, Dassel, Germany). Rabbit polyclonal antibodies against murine Sepp,<sup>33</sup> Lrp8 (kindly provided by Prof. Dr Herz, UT Dallas, TX, USA) and Lrp1 (abcam, Cambridge, UK) were used and quantified by ECL<sup>TM</sup> Western Blotting Detection Reagents (GE Healthcare, UK).

### Selenium (Se) determination

Se concentrations were quantified by total reflection X-ray fluorescence (TXRF) spectroscopy using a PICOFOX S2 spectrometer (Bruker Nano GmbH, Berlin, Germany). Briefly, bones were weighed, decalcified in 2.5% nitric acid solution for 2–3 h and dissolved in 65% nitric acid for 1 h at 70 °C. The acidic homogenates were supplemented with Gallium (Ga) as an internal standard (1000  $\mu\text{g}$  Ga  $\text{l}^{-1}$ , f.c.). Alternatively, bones were treated over night at 56 °C with proteinase K (10 mM Tris pH 8.0; 100 mM NaCl; 50 mM EDTA pH 8.0; 0.5% SDS and 10 mg  $\text{ml}^{-1}$  proteinase K), and soluble material was separated from insoluble minerals and analysed as above. Serum was diluted 1:2 with the Ga standard. Duplicates of samples (8  $\mu\text{l}$  each) were placed on polished quartz glass sample carriers, air-dried and analysed. The intra-assay coefficient of variation was determined with a standard serum (Sero AS, Billingstad, Norway) and was less than 10% during the measurements. The limits of quantification were tested by serial dilutions of serum and bone homogenate samples. The measurements yielded linear dilution-dependent Se signals in samples with final concentrations down to only 1.0  $\mu\text{g}$  Se  $\text{l}^{-1}$  serum and 0.01  $\mu\text{g}$  Se  $\text{g}^{-1}$  bone homogenate, respectively.

### In silico analyses

The expression profiles of murine selenoprotein genes and genes involved in selenoprotein metabolism were extracted from the BioGPS database (www.biogps.org) and differences between murine osteoblasts and osteoclasts were determined.


### Statistics

Statistical analyses were performed with GraphPad Prism v.4.0 (GraphPad Software Inc., San Diego, USA) and IBM SPSS Statistics 19 (IBM Corporation, Armonk, USA). Trace element concentrations are represented as means  $\pm$  SD. Two groups were compared with Student's  $t$ -test, and multiple groups with One-way ANOVA and Bonferroni's Multiple Comparison Test. Numbers of animals tested are specified in the respective figure legends. Spearman's coefficient of correlation was determined to assess the association between Se levels of serum and bones. Dunnett's  $t$  test (two-tailed) was used to analyse differences in expression levels. Statistical significance was assigned if  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) or  $P < 0.001$  (\*\*\*).

## Results

### Bone Se status is resistant to low Se concentrations

Se concentrations in serum and peripheral tissues are known to decline in the absence of SePP. Accordingly, serum Se concentrations are reduced in Sepp<sup>+/-</sup> and marginal in Sepp<sup>-/-</sup> mice (Fig. 1A). In order to analyse bone Se status, femur and tibia from adult mice were chosen as these bones can easily be prepared, are of sufficient size for biochemical and trace



**Fig. 1** Bone Se concentrations in serum and bones according to genotypes. (A) Serum Se levels are strongly reduced in Sepp<sup>+/-</sup> and Sepp<sup>-/-</sup> as compared to Sepp<sup>+/+</sup> littermates. (B) Se concentrations decline according to the genotype in both bone types tested, i.e., in femur and tibia. (C) Se concentrations correlate positively between serum and bones (Spearman's rank correlation;  $r = 0.9420$ ;  $P < 0.0001$ ). Strong differences in serum are only mildly reflected in bones. Values are expressed as means  $\pm$  SD ( $n = 6$ ), and were evaluated by one-way ANOVA and Bonferroni's Multiple Comparison Test;  $P < 0.05$  (\*),  $P < 0.01$  (\*\*),  $P < 0.001$  (\*\*\*).



element analyses and are important regulators of body size and mineral homeostasis. Se concentrations were comparable in both bone types (Fig. 1B). Comparing all mouse groups, *i.e.* females and males of the three different genotypes, serum and bone Se concentrations show a strong positive linear correlation (Fig. 1C). However, differences in serum Se levels are not linearly reflected in bones; while serum Se concentrations differ between  $\text{Sepp}^{+/+}$  and  $\text{Sepp}^{-/-}$  mice by up to 25-fold, the respective Se values in bones differ by 2.5-fold only. This apparent resistance of bones towards strongly diminished circulating Sepp and Se concentrations indicates that bones are preferentially supplied tissues residing high in the hierarchy of Se target tissues.

### Se associates with bone proteins but not with minerals

Bones are composed of roughly 1/3 organic components and 2/3 inorganic minerals. In order to localize Se within these principal components, murine femur and tibia samples were either digested by proteinase K thereby removing the organic protein components and generating a rigid brittle mineral-rich scaffold, or were treated by 2.5% nitric acid thereby dissolving the inorganic minerals leaving behind a flexible protein-rich bone matrix (Fig. 2A and B). Upon trace element analyses, Se was associated exclusively with the protein-rich samples and not with the inorganic matrix (Fig. 2C) indicating that Se is metabolized in bones into organic structures, *i.e.* selenoproteins, and not inserted by chemical reactions into hydroxyapatite or other minerals. This is in contrast to other trace elements like *e.g.* fluorine, which becomes predominantly inserted into apatite. Length of bones is slightly reduced in  $\text{Sepp}^{-/-}$  as compared to  $\text{Sepp}^{+/+}$  mice (Fig. 2D).

### Expression of selenoproteins and Se metabolism genes in bones

Next, mRNA expression patterns of selenoprotein genes together with central factors involved in selenoprotein biosynthesis and Se metabolism were analysed in bone samples of the different genotypes. An impressive set of 22 out of the maximally possible 24 selenoprotein genes were detected on the transcript level with the only notable exceptions of *Dio1* and *Selv* (Table 1). These findings are compatible with former studies reporting a selective lack of *Dio1* in bones,<sup>34</sup> or *Dio1* and *Selv* in chondrocytes.<sup>35</sup> A respective *in silico* analysis of expressed genes yields compatible results and offers insights into cell-specific expression profiles in osteoblasts *versus* osteoclasts (Table S2, ESI†). Notably, expression of genes encoding the protective enzymes *Txrd1-3* and *Gpx1,-2,-4* along with the Sepp receptor *Lrp8* is higher in osteoclast than in osteoblasts, while the ER-function and quality-associated genes *Sepn*, *Sep15*, *Sepw*, *Selk*, *Selm* and *Seps* are more abundantly expressed in osteoblasts. This finding nicely conforms to the major catabolic and anabolic functions of osteoclasts and osteoblasts, respectively.

### Resistance of bone selenoprotein expression to Se deficiency

In contrast to expectations, mRNA levels of most of the selenoproteins detected in bones were not strongly affected by the




Fig. 2 Se is localized in bone organic matter. (A) Murine femurs were prepared free of surrounding tissue and treated by proteinase K to dissolve organic material. (B) Murine femurs were decalcified in a 2.5% nitric acid solution to obtain bendable mineral-free bone specimen. (C) Se was analyzed in preparations from adult  $\text{Sepp}^{+/+}$  and  $\text{Sepp}^{+/-}$  mice, and was exclusively associated with the protein fractions but not with minerals. (D) Bone lengths do not differ between  $\text{Sepp}^{+/+}$  and  $\text{Sepp}^{+/-}$  mice. Values are expressed as means ± SD ( $n = 6$ ).


$\text{Sepp}$  genotype, *i.e.*, by a moderate or strong decline in serum Se concentrations. In line with the genotypes,  $\text{Sepp}$  mRNA was strongly reduced in heterozygous animals and not detectable in  $\text{Sepp}^{-/-}$  mice (Table 1). Along with  $\text{Sepp}$  mRNA, significant differences were also seen in the expression of *Txrd3* and *Selo* between  $\text{Sepp}^{+/+}$  and  $\text{Sepp}^{+/-}$  littermates. However, strong alterations can be noted in  $\text{Sepp}^{-/-}$  knockout mice; transcript concentrations of *Gpx2-4*, *Selk* and *Selm* are significantly reduced, while *Lrp1* and *Lrp8* are up-regulated. Notably, *Dio1*, *Selv* and *Lrp2* were not detectable in any of the bone RNA preparations.

### Sepp receptor Lrp8 is induced in Se-deficient bones

In accordance with the high number of selenoprotein transcripts, also all the essential factors for Se metabolism and selenoprotein biosynthesis are expressed in bones (Table 1). Of the well-established SePP receptors, *Lrp8* was








**Fig. 3** Sepp and its receptor Lrp8 are expressed in bones. Femurs of mice with the indicated genotypes were isolated, homogenized, size fractionated by SDS-PAGE and analysed by Western Blot. (A) SePP was expressed in Sepp<sup>+/+</sup> and Sepp<sup>+/-</sup> but absent in Sepp<sup>-/-</sup> mice. (B) Lrp8 was present in bones of all genotypes at expression levels almost comparable to testes. (C, D) Sepp expression showed a characteristic staining pattern in mineralized bones, but not in cartilage.

detectable and Lrp2 was absent; Lrp8 was strongly up-regulated in Sepp<sup>-/-</sup> mice. A similar regulation was observed for the third Lrp family member tested, *i.e.*, Lrp1. Whether Lrp1 also contributes to SePP uptake is currently a matter of debate. As SePP and Lrp8 have been established to form a central transporter–receptor pair for tissue-specific Se uptake,<sup>36</sup> their protein expression was evaluated by Western Blot analysis (Fig. 3). Sepp is detectable in femurs of Sepp<sup>+/+</sup> and Sepp<sup>+/-</sup> mice with bands migrating at approximately 47, 45 and 42 kDa. As expected, expression of Sepp is undetectable in Sepp<sup>-/-</sup> mice (Fig. 3A). Lrp8 is detected in bones of all three Sepp genotypes with isoforms migrating at >130 and >180 kDa (Fig. 3B). Lrp8 expression in bones is of almost similar strength as in testes which served as the positive control tissue.<sup>16</sup> Bones are thus well equipped for SePP-mediated Se uptake.

In histochemical analyses, Sepp can be detected especially in mineralized bones while cartilage was negative (Fig. 3C and D).

### Se is transported to bones by selenoprotein P (SePP)

Next, we tested whether bones can efficiently increase their Se status by using circulating SePP, *i.e.*, whether Sepp transports Se from liver to bones. To this end, Sepp<sup>-/-tg</sup> mice expressing a human SePP transgene in hepatocytes only were analysed. Se concentrations in serum were only marginally affected by the transgene (Fig. 4A). In comparison, Se concentrations in femurs and tibia of Sepp<sup>-/-tg</sup> were efficiently increased by the transgene as compared to Sepp<sup>-/-</sup> mice (Fig. 4B). Notably, bone Se concentrations in Sepp<sup>-/-tg</sup> mice reached almost levels of heterozygous Sepp<sup>+/-</sup> mice despite the minor contribution of the transgene to serum Se. This finding indicates an efficient Se transport into bones by hepatically-derived SePP (Fig. 4C).



**Fig. 4** Role of SePP as the Se transporter for bones. (A) Serum Se increases only marginally in Sepp<sup>-/-tg</sup> as compared to Sepp<sup>-/-</sup> mice. (B) In comparison, Se concentrations in femur (hatched bars) and tibia (open bars) increase significantly in Sepp<sup>-/-tg</sup> mice as compared to Sepp<sup>-/-</sup> mice upon expression of SePP in hepatocytes. Values are expressed as means  $\pm$  SD ( $n = 6$ ) and were evaluated by one-way ANOVA and Bonferroni's Multiple Comparison Test;  $P < 0.05$  (\*),  $P < 0.01$  (\*\*) or  $P < 0.001$  (\*\*\*). (C) Under normal conditions, dietary Se is taken up by hepatocytes, efficiently inserted into SePP and transported to preferential supplied target tissues including bones. Severe Se deficiency or chronic liver diseases cause SePP deficiency and Se deficits in bones leading to diminished expression of certain selenoproteins and a compensatory up regulation of Lrp8 as the bone SePP receptor. These findings add SePP to the list of important liver-derived factors for bone health and as a potential supplementation target in hepatic osteodystrophy.

## Discussion

The scientific and medical interest into the importance of Se intake and Se status for general health and disease prevention has increased tremendously during the last few decades. Several experimental animal studies and human analyses have contributed to the current notion that this trace element is of high relevance for common human diseases including cancer, diabetes and inflammatory diseases, and that many subjects are insufficiently supplied by their diet.<sup>1</sup> Severe Se deficiency is associated with growth defects and impaired mineralization in animal studies.<sup>20,21,25</sup> A recent study reported on increased bone resorption and disturbed bone microarchitecture in Se-deficient mice.<sup>37</sup> However, insights into the molecular role of specific selenoproteins in bone physiology are sparse. The available information has been reviewed recently highlighting some important knowledge gaps.<sup>24</sup> Our identification of Sepp as the transporter of Se from liver into bone resolves an essential metabolic pathway.

We decided to first establish a robust protocol for Se analysis from bones with the aim of separating inorganic minerals from the organic matrix. Our results indicate that in bones Se is exclusively associated with selenoproteins. Demineralization of bones is a suitable way of preparing the tissue for Se



quantification and speciation. However, our analyses did not provide spatial information on the distribution of Se in bones, which needs further analyses. The Se concentrations obtained are compatible with respective data from human bones ( $0.17 \pm 0.04 \mu\text{g g}^{-1}$ ).<sup>38</sup> In comparison to other tissues, Se concentrations in bones are in the same range as in brain or muscles ( $0.15\text{--}0.30 \mu\text{g g}^{-1}$ ), but significantly lower than in liver, kidneys or testes ( $0.7\text{--}1.5 \mu\text{g g}^{-1}$ ) of mice fed an adequate Se diet.<sup>39</sup> However, upon limited Se supply or SePP deficiency, liver and kidneys are depleted from their Se content, while brain and testes are relatively resistant.<sup>40</sup> Our results indicate that bones belong to the preferentially supplied tissues, too. This notion is supported by the robust expression of Lrp8 mRNA and protein in bones as this receptor has been proven to be decisively involved in tissue-specific SePP-mediated Se uptake.<sup>36</sup> Together with the expression of SePP and SePP-receptors in bones, an efficient local biosynthesis and reuptake circuit can be envisaged similar to the “SePP-cycle” suggested for the homeostatic mechanism maintaining brain Se concentrations against an adverse gradient in blood safeguarding high tissue Se levels in Se deficiency.<sup>41</sup>

Most of the biochemically characterized selenoproteins catalyse redox reactions, often linked to antioxidative protection, repair of oxidized proteins or quality control of secreted proteins.<sup>42</sup> These functions may be of central importance for bone turnover in view of the important role of reactive oxygen species during bone remodelling and as endogenous signals for osteoclastogenesis and osteoblast activities.<sup>24</sup> Besides the selenoproteins being implicated in these functions, the thyroid hormone activating selenoprotein Dio2 has been shown to decisively affect mineralization and bone quality.<sup>43</sup> However, it is unlikely that bone Dio2 activity is strongly affected in our mice as the mRNA levels remained fairly constant and translation of Dio2 is hierarchically preferred during limited Se supply and impaired SePP expression.<sup>44</sup>

To our knowledge, this is the first in-depth analysis of Se supply to bones. Changes in gene expression in response to reduced or missing SePP expression are of relevance as SePP is a valid biomarker for Se status and functional polymorphisms in human SePP are described.<sup>45</sup> The up-regulation of Lrp8 in Se deficiency may constitute a meaningful feedback mechanism for avoiding critically low bone selenoprotein expression levels endangering full bone functionality.

This hypothesis needs to be tested in future experiments. Notably, chronic liver disease negatively affects bone health, known as hepatic osteodystrophy, likely caused by insufficient IGF-1, vitamin D and vitamin K biosynthesis and transport.<sup>46</sup> It needs to be tested, in how far impaired Se transport to bones via low SePP secretion from liver contributes to the increased osteoporosis and osteopenia risk in patients with chronic liver disease, and whether Se substitution is an effective adjuvant treatment option in patients with chronic liver disease.

## Conclusions

Bones are hierarchically well-supplied SePP-target tissues largely resistant to low Se concentrations in blood. Bones express an

almost complete set of selenoproteins and all the factors needed for selenoprotein biosynthesis. When exposed to strong SePP deficiency, bones react by up-regulating the gene expression of the SePP receptor Lrp8. As of now, this metabolic response to a low intracellular Se level is unique to bones. It remains to be seen whether such a dynamic adaptation of SePP uptake and intracellular Se metabolism represents a more general mechanism of SePP-target tissues in Se deficiency, contributing to the hierarchical supply of essential tissues like the brain and endocrine organs and safeguarding vital Se-dependent processes in times of Se shortage.

## Acknowledgements

We thank Katja Schreiber and Carola Geiler for excellent technical assistance, and Drs Joseph Köhrle, Peter J. Hofmann, Eva Wirth, Andrea Schütte and Niels-P. Becker for inspiring discussions as well as experimental support. We are indebted to Prof. Dr J. Herz, UT Dallas, USA, for providing the Lrp8 antibody used in our analysis, and to the BioGPS team for doing a great job. This study was supported by BSRT, Deutsche Forschungsgemeinschaft (DFG; GraKo 1208, SCHO849/4-1) and Federal Ministry of Economics and Technology (BMW; KF2263202CS2).

## References

- 1 M. P. Rayman, *Lancet*, 2012, **379**, 1256–1268.
- 2 C. D. Davis, P. A. Tsuji and J. A. Milner, *Annu. Rev. Nutr.*, 2012, **32**, 73–95.
- 3 M. W. Angstwurm, L. Engelmann, T. Zimmermann, C. Lehmann, C. H. Spes, P. Abel, R. Strauss, A. Meier-Hellmann, R. Insel, J. Radke, J. Schüttler and R. Gärtner, *Crit. Care Med.*, 2007, **35**, 118–126.
- 4 H. A. Meyer, T. Endermann, C. Stephan, M. Stoedter, T. Behrends, I. Wolff, K. Jung and L. Schomburg, *PLoS One*, 2012, **7**, e46644.
- 5 M. P. Rayman, *Br. J. Nutr.*, 2008, **100**, 254–268.
- 6 G. F. Combs, Jr., *Br. J. Nutr.*, 2001, **85**, 517–547.
- 7 D. Behne and A. Kyriakopoulos, *Am. J. Clin. Nutr.*, 1993, **57**, 310S–312S.
- 8 J. R. Arthur, G. Bermano, J. H. Mitchell and J. E. Hesketh, *Biochem. Soc. Trans.*, 1996, **24**, 384–388.
- 9 L. Schomburg and U. Schweizer, *Biochim. Biophys. Acta*, 2009, **1790**, 1453–1462.
- 10 G. V. Kryukov, S. Castellano, S. V. Novoselov, A. V. Lobanov, O. Zehtab, R. Guigo and V. N. Gladyshev, *Science*, 2003, **300**, 1439–1443.
- 11 C. Allmang, L. Wurth and A. Krol, *Biochim. Biophys. Acta*, 2009, **1790**, 1415–1423.
- 12 M. P. Bansal, C. J. Oborn, K. G. Danielson and D. Medina, *Carcinogenesis*, 1989, **10**, 541–546.
- 13 R. F. Burk and K. E. Hill, *Annu. Rev. Nutr.*, 2005, **25**, 215–235.
- 14 K. Renko, M. Werner, I. Renner-Müller, T. G. Cooper, C. H. Yeung, B. Hollenbach, M. Scharpf, J. Köhrle, L. Schomburg and U. Schweizer, *Biochem. J.*, 2008, **409**, 741–749.



- 15 G. E. Olson, V. P. Winfrey, K. E. Hill and R. F. Burk, *J. Biol. Chem.*, 2008, **283**, 6854–6860.
- 16 G. E. Olson, V. P. Winfrey, S. K. Nagdas, K. E. Hill and R. F. Burk, *J. Biol. Chem.*, 2007, **282**, 12290–12297.
- 17 Y. Xia, K. E. Hill, P. Li, J. Xu, D. Zhou, A. K. Motley, L. Wang, D. W. Byrne and R. F. Burk, *Am. J. Clin. Nutr.*, 2010, **92**, 525–531.
- 18 J. Hoefflich, B. Hollenbach, T. Behrends, A. Hoeg, H. Stosnach and L. Schomburg, *Br. J. Nutr.*, 2010, **104**, 1601–1604.
- 19 M. Conrad and U. Schweizer, *Antioxid. Redox Signaling*, 2010, **12**, 851–865.
- 20 L. Schomburg, U. Schweizer, B. Holtmann, L. Flohé, M. Sendtner and J. Köhrle, *Biochem. J.*, 2003, **370**, 397–402.
- 21 K. E. Hill, J. Zhou, W. J. McMahan, A. K. Motley, J. F. Atkins, R. F. Gesteland and R. F. Burk, *J. Biol. Chem.*, 2003, **278**, 13640–13646.
- 22 R. F. Burk, K. E. Hill, G. E. Olson, E. J. Weeber, A. K. Motley, V. P. Winfrey and L. M. Austin, *J. Neurosci.*, 2007, **27**, 6207–6211.
- 23 W. M. Valentine, T. W. Abel, K. E. Hill, L. M. Austin and R. F. Burk, *J. Neuropathol. Exp. Neurol.*, 2008, **67**, 68–77.
- 24 H. Zeng, J. J. Cao and G. F. Jr. Combs, *Nutrients*, 2013, **5**, 97–110.
- 25 R. Moreno-Reyes, D. Egrise, M. Boelaert, S. Goldman and S. Meuris, *J. Nutr.*, 2006, **136**, 595–600.
- 26 R. Moreno-Reyes, C. Suetens, F. Mathieu, F. Begaux, D. Zhu, M. T. Rivera, M. Boelaert, J. Neve, N. Perlmutter and J. Vanderpas, *N. Engl. J. Med.*, 1998, **339**, 1112–1120.
- 27 A. M. Dumitrescu, X. H. Liao, M. S. Abdullah, J. Lado-Abeal, F. A. Majed, L. C. Moeller, G. Boran, L. Schomburg, R. E. Weiss and S. Refetoff, *Nat. Genet.*, 2005, **37**, 1247–1252.
- 28 C. Di Cosmo, N. McLellan, X. H. Liao, K. K. Khanna, R. E. Weiss, L. Papp and S. Refetoff, *J. Clin. Endocrinol. Metab.*, 2009, **94**, 4003–4009.
- 29 M. F. Azevedo, G. B. Barra, L. A. Naves, L. F. Ribeiro Velasco, P. Godoy Garcia Castro, L. C. de Castro, A. A. Amato, A. Miniard, D. Driscoll, L. Schomburg and F. de Assis Rocha Neves, *J. Clin. Endocrinol. Metab.*, 2010, **95**, 4066–4071.
- 30 A. Hoeg, A. Gogakos, E. Murphy, S. Mueller, J. Köhrle, D. M. Reid, C. C. Gluer, D. Felsenberg, C. Roux, R. Eastell, L. Schomburg and G. R. Williams, *J. Clin. Endocrinol. Metab.*, 2012, **97**, 4061–4070.
- 31 J. Chiu-Ugalde, F. Theilig, T. Behrends, J. Drebes, C. Sieland, P. Subbarayal, J. Köhrle, A. Hammes, L. Schomburg and U. Schweizer, *Biochem. J.*, 2010, **431**, 103–111.
- 32 A. Untergasser, H. Nijveen, X. Rao, T. Bisseling, R. Geurts and J. A. Leunissen, *Nucleic Acids Res.*, 2007, **35**, W71–W74.
- 33 U. Schweizer, M. Michaelis, J. Köhrle and L. Schomburg, *Biochem. J.*, 2004, **378**, 21–26.
- 34 A. J. Williams, H. Robson, M. H. Kester, J. P. van Leeuwen, S. M. Shalet, T. J. Visser and G. R. Williams, *Bone*, 2008, **43**, 126–134.
- 35 J. Yan, Y. Zheng, Z. Min, Q. Ning and S. Lu, *Biometals*, 2013, **26**, 285–296.
- 36 S. Kurokawa, K. E. Hill, W. H. McDonald and R. F. Burk, *J. Biol. Chem.*, 2012, **287**, 28717–28726.
- 37 J. J. Cao, B. R. Gregoire and H. Zeng, *J. Nutr.*, 2012, **142**, 1526–1531.
- 38 C.-T. Wang, W.-T. Chang, K.-C. Huang and R.-T. Wang, *Anal. Sci.*, 1997, **13**, 497–500.
- 39 A. Nakayama, K. E. Hill, L. M. Austin, A. K. Motley and R. F. Burk, *J. Nutr.*, 2007, **137**, 690–693.
- 40 G. Bermano, F. Nicol, J. A. Dyer, R. A. Sunde, G. J. Beckett, J. R. Arthur and J. E. Hesketh, *Biochem. J.*, 1995, **311**(pt 2), 425–430.
- 41 L. Schomburg, U. Schweizer and J. Köhrle, *Cell. Mol. Life Sci.*, 2004, **61**, 1988–1995.
- 42 M. V. Kasaikina, D. L. Hatfield and V. N. Gladyshev, *Biochim. Biophys. Acta*, 2012, **1823**, 1633–1642.
- 43 J. H. Bassett, A. Boyde, P. G. Howell, R. H. Bassett, T. M. Galliford, M. Archanco, H. Evans, M. A. Lawson, P. Croucher, D. L. St Germain, V. A. Galton and G. R. Williams, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 7604–7609.
- 44 L. Schomburg, C. Riese, M. Michaelis, E. Griebert, M. O. Klein, R. Sapin, U. Schweizer and J. Köhrle, *Endocrinology*, 2006, **147**, 1306–1313.
- 45 C. Meplan, L. K. Crosley, F. Nicol, G. J. Beckett, A. F. Howie, K. E. Hill, G. Horgan, J. C. Mathers, J. R. Arthur and J. E. Hesketh, *FASEB J.*, 2007, **21**, 3063–3074.
- 46 G. Lopez-Larramona, A. J. Lucendo, S. Gonzalez-Castillo and J. M. Tenias, *World J. Hepatol.*, 2011, **3**, 300–307.

